Cardiogenomics Market Report 2026

Cardiogenomics Market Overview

• Cardiogenomics market size has reached to $1.74 billion in 2025 • Expected to grow to $3.57 billion in 2030 at a compound annual growth rate (CAGR) of 15.4% • Growth Driver: Increasing Demand For Personalized Medicine Driving The Market Due To Advances In Genomics And Tailored Treatment Approaches • Market Trend: Advancements In Genomic Medicine For Early Detection And Personalized Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cardiogenomics Market?

Cardiogenomics refers to the scientific study of how variations in an individual’s genetic makeup influence the risk, onset, and progression of cardiovascular diseases. It plays a crucial role in enabling personalized prevention, accurate diagnosis, and targeted treatment strategies for improved heart health outcomes. The main product types of cardiogenomics are testing kits, reagents, instruments, software, and services. Testing kits refers to packaged tools and consumables designed to perform specific genetic tests. The technologies employed comprise next-generation sequencing, polymerase chain reaction, microarrays, and others. These are applied in applications including congenital heart diseases, cardiomyopathies, arrhythmias, coronary artery disease, and others, and serving end-users including hospitals and clinics, diagnostic laboratories, research institutes, and others.

What Is The Cardiogenomics Market Growth Forecast?

The cardiogenomics market size is expected to see rapid growth in the next few years. It will grow to $3.57 billion in 2030 at a compound annual growth rate (CAGR) of 15.4%. The growth in the forecast period can be attributed to increasing demand for personalized cardiac care, expansion of precision medicine initiatives, rising investments in genomic research, growing adoption of AI-driven genomic analysis, increased integration of genomics into routine cardiology practice. Major trends in the forecast period include increasing adoption of genetic risk profiling in cardiology, rising use of next-generation sequencing in heart disease research, growing integration of bioinformatics platforms, expansion of personalized cardiovascular treatment approaches, enhanced focus on preventive genomic screening.

Global Cardiogenomics Market Segmentation

1) By Product Type: Testing Kits, Reagents, Instruments, Software, Services 2) By Technology: Next-Generation Sequencing, Polymerase Chain Reaction, Microarray, Other Technologies 3) By Application: Congenital Heart Diseases, Cardiomyopathies, Arrhythmias, Coronary Artery Disease, Other Applications 4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Research Institutes, Other End-Users Subsegments: 1) By Testing Kits: PCR (Polymerase Chain Reaction) kits, Microarray kits, NGS (Next Generation Sequencing) kits 2) By Reagents: Enzymes, Probes, Buffers 3) By Instruments: Sequencers, Genotyping instruments, Microarray Scanners 4) By Software: Data Analysis Software, Reporting Platforms, Bioinformatics Tools 5) By Services: Genetic Testing Services, Counseling Services, Data Analysis Services

What Is The Driver Of The Cardiogenomics Market?

The increasing demand for personalized medicine is expected to propel the growth of the cardiogenomics market going forward. Personalized medicine refers to a healthcare approach that tailors prevention, diagnosis, and treatment to an individual’s genetic, environmental, and lifestyle factors. Increasing personalized medicine is driven by advances in genomics, allowing deeper understanding of individual genetic variations and enabling more precise, targeted treatments that improve patient outcomes and reduce trial-and-error in therapies. Cardiogenomics supports personalized medicine by using genetic insights to tailor cardiovascular disease prevention, diagnosis, and treatment to an individual’s unique genetic profile. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the increasing demand for personalized medicine is driving the growth of the cardiogenomics industry.

Key Players In The Global Cardiogenomics Market

Major companies operating in the cardiogenomics market are Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings (Labcorp), Quest Diagnostics Incorporated, Illumina Inc., QIAGEN N.V., Myriad Genetics Inc., ARUP Laboratories, BGI Genomics Co. Ltd., Invitae Corporation, GeneDx Inc., Helix OpCo LLC, SOPHiA GENETICS SA, Baylor Genetics, Blueprint Genetics, Novogenia GmbH, Veritas Genetics, Dante Genomics, Gene by Gene Ltd., GENinCode Plc., UAB Cardiogenomics Clinic

Global Cardiogenomics Market Trends and Insights

Major companies operating in the cardiogenomics market are focusing on developing innovative solutions such as oncogenomics to enhance early detection and personalized treatment of cardiovascular-related cancers. Oncogenomics refers to the study of cancer-related genes and their mutations to understand cancer development and progression and to develop targeted therapies and personalized treatment approaches. For instance, in April 2025, Fortis Healthcare Ltd., an India-based healthcare company, launched a Fortis Institute of Genomic Medicine in India to advance genetic research and personalized medicine. It transforms patient care by enabling early disease detection, precise diagnosis, and personalized treatment across specialties such as oncology, cardiology, and neurology. It empowers targeted therapies, improves treatment outcomes, and supports preventive care for hereditary conditions. The institute’s purpose is to advance precision medicine through a multidisciplinary team and innovative technologies, making healthcare more personalized and effective for Indian patients.

What Are Latest Mergers And Acquisitions In The Cardiogenomics Market?

In March 2025, Tempus AI Inc., a US-based technology company, acquired Ambry Genetics Corporation for an undisclosed amount. With this acquisition, Tempus AI Inc. aims to leverage genetic testing and AI-driven data to expand its precision medicine capabilities, improve patient outcomes, and provide comprehensive, personalized healthcare across multiple disease areas. Ambry Genetics Corporation is a US-based genetic testing and precision medicine company that offers cardiogenomics services.

Regional Outlook

North America was the largest region in the cardiogenomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cardiogenomics Market?

The cardiogenomics market consists of revenues earned by entities by providing services such as genetic testing and screening, risk assessment and prediction, and counseling services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiogenomics market also includes sales of cardiogenomic testing panels, genetic testing panels, and direct-to-consumer (DTC) genetic tests. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cardiogenomics Market Report 2026?

The cardiogenomics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cardiogenomics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.